Insmed (INSM) Competitors $165.31 -2.60 (-1.55%) Closing price 04:00 PM EasternExtended Trading$165.50 +0.19 (+0.11%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. SNY, GSK, ARGX, TAK, ONC, BNTX, TEVA, GMAB, SMMT, and ASNDShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Sanofi (SNY), GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Insmed vs. Its Competitors Sanofi GSK argenex Takeda Pharmaceutical BeOne Medicines BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Insmed (NASDAQ:INSM) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Which has higher earnings & valuation, INSM or SNY? Sanofi has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$363.71M96.07-$913.77M-$5.71-28.95Sanofi$44.46B2.74$6.02B$4.1611.94 Is INSM or SNY more profitable? Sanofi has a net margin of 21.47% compared to Insmed's net margin of -259.82%. Sanofi's return on equity of 16.86% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-259.82% -195.37% -49.49% Sanofi 21.47%16.86%9.63% Does the media prefer INSM or SNY? In the previous week, Insmed had 2 more articles in the media than Sanofi. MarketBeat recorded 18 mentions for Insmed and 16 mentions for Sanofi. Insmed's average media sentiment score of 0.95 beat Sanofi's score of 0.91 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 12 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 8 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer INSM or SNY? Insmed presently has a consensus price target of $152.88, indicating a potential downside of 7.52%. Sanofi has a consensus price target of $62.67, indicating a potential upside of 26.19%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 1 Sell rating(s) 1 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.86Sanofi 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility & risk, INSM or SNY? Insmed has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Do insiders & institutionals believe in INSM or SNY? 14.0% of Sanofi shares are held by institutional investors. 3.0% of Insmed shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummarySanofi beats Insmed on 11 of the 17 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.49B$3.48B$6.18B$10.69BDividend YieldN/A2.26%5.72%4.83%P/E Ratio-28.958.2420.7722.98Price / Sales96.07481.95579.80129.94Price / CashN/A47.5937.5161.65Price / Book103.3210.6612.476.59Net Income-$913.77M-$52.56M$3.32B$276.14M7 Day Performance2.44%4.97%1.87%0.01%1 Month Performance14.20%16.48%8.40%3.60%1 Year Performance128.71%14.95%63.49%32.76% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.0579 of 5 stars$165.31-1.5%$152.88-7.5%+125.3%$35.49B$363.71M-28.951,271Analyst ForecastSNYSanofi4.4184 of 5 stars$48.80+1.5%$62.67+28.4%-9.5%$119.83B$44.46B11.7382,878Upcoming EarningsGSKGSK1.8783 of 5 stars$43.67+0.3%$37.38-14.4%+14.4%$88.83B$31.63B20.2268,629Dividend CutARGXargenex3.2485 of 5 stars$799.56+0.3%$817.53+2.2%+50.3%$48.93B$3.05B41.001,599TAKTakeda Pharmaceutical2.5401 of 5 stars$13.72+0.0%N/A-1.8%$43.64B$4.48T45.7247,455ONCBeOne Medicines3.041 of 5 stars$327.03+2.2%$340.30+4.1%N/A$35.84B$3.81B-189.0311,000Analyst ForecastBNTXBioNTech2.6813 of 5 stars$102.30+0.2%$134.32+31.3%-3.4%$24.59B$2.88B-63.946,772News CoverageTEVATeva Pharmaceutical Industries3.4852 of 5 stars$20.02-0.1%$25.57+27.8%+8.2%$22.96B$16.63B-125.0936,830News CoveragePositive NewsGMABGenmab A/S3.8788 of 5 stars$32.68+2.7%$40.80+24.8%+32.9%$20.98B$3.12B16.422,682Positive NewsAnalyst DowngradeShort Interest ↑Analyst RevisionSMMTSummit Therapeutics3.0356 of 5 stars$22.93+7.4%$31.29+36.4%-5.6%$17.03B$700K-22.70110Trending NewsEarnings ReportAnalyst ForecastOptions VolumeASNDAscendis Pharma A/S3.0349 of 5 stars$208.43-0.5%$248.29+19.1%+58.0%$12.86B$393.54M-40.391,017News CoverageAnalyst UpgradeGap Up Related Companies and Tools Related Companies Sanofi Competitors GSK Competitors argenex Competitors Takeda Pharmaceutical Competitors BeOne Medicines Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
